Curr Breast Cancer Rep (2017) 9:173–182 DOI 10.1007/s12609-017-0249-4 CLINICAL TRIALS (PF PEDDI, SECTION EDITOR) Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients With Breast Cancer 1 2 3 4 Somaira Nowsheen & Paul V Viscuse & Ciara C. O’Sullivan & Nicole P. Sandhu & 3 5 6 7 8 Tufia C. Haddad & Anne Blaes & Jennifer Klemp & Lara Nhola & Joerg Herrmann & Kathryn J. Ruddy Published online: 14 July 2017 Springer Science+Business Media, LLC 2017 Abstract function in most cases. Severe trastuzumab-induced Purpose of Review Treatment with trastuzumab is a cornerstone cardiotoxicity is rare enough that the risk-benefit ratio still of human epidermal growth factor receptor 2 (HER2)-overex- weighs in favor of its use in the vast majority of patients with pressing breast cancer treatment, but carries an unfortunate risk HER2+ breast cancer. of toxicity to the cardiovascular system. Here, we review recent Summary An improved understanding of the pathophysiolo- findings on trastuzumab-associated cardiotoxicity, focusing on gy underlying trastuzumab-induced cardiotoxicity and the its incidence, diagnosis, and treatment. identification of patients at highest risk will allow us to con- Recent Findings Screening with multigated acquisition scan tinue to safely administer trastuzumab in patients with
Current Breast Cancer Reports – Springer Journals
Published: Jul 14, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera